Table 1.
Characteristics of the Sleep and Asthma Cohort (SAC) study population (N = 197) that completed at least 3 spirometry over a minimum of 1 year
| Participant characteristic | N=197 |
|---|---|
|
| |
| Prospective follow-up (years) | Median 4.7; IQR 3.3–5.4 |
| Range 1.1 to 6.5 | |
|
| |
| Number of spirometry evaluations per patient, n (%) | |
|
| |
| 3 | 53 (26.9) |
|
| |
| 4 | 39 (19.8) |
|
| |
| 5 | 54 (27.4) |
|
| |
| 6 | 26 (13.2) |
|
| |
| 7 | 14 (7.1) |
|
| |
| 8 | 11 (5.6) |
|
| |
| Age at first spirometry (years) | Median 10.7, IQR 8.0–14.2 |
| Range 4 to 19.3 | |
|
| |
| Gender, male, N (%) | 94 (47.7) |
|
| |
| Hemoglobin (g/dl), mean (std. dev.) | 8.2 (1.2) |
|
| |
| WBC (k/mm3), mean (std. dev.) | 11.7 (3.6) |
|
| |
| Reticulocyte (%), mean (std. dev.) (N=196) | 11.4 (5.6) |
|
| |
| Has asthma, N (%) | 58 (29.4) |
|
| |
| On hydroxyurea at first spirometry, N (%), (N=194) | 24 (12.4) |
|
| |
| On hydroxyurea during study period, N (%), (N=194) | 64 (33.0) |
|
| |
| On ICS at first spirometry, N (%) | 40 (20.3) |
|
| |
| On ICS during study period, N (%) | 56 (28.4) |
|
| |
| BD response >=12.0, n (%), (N=191) | 32 (16.8) |
|
| |
| ACS rate during study period, per year, mean (std. dev.) | 0.24 (0.36) |
|
| |
| Pain rate during study period, per year, mean (std. dev.) | 0.86, (1.23) |
|
| |
| FEV1% predicted at first spirometry, mean (std. dev.) | 88.48 (13.04) |
|
| |
| FEV1% predicted at last spirometry, mean (std. dev.) | 87.88 (12.77) |
|
| |
| FVC% predicted at first spirometry, mean (std. dev.) | 92.78 (13.68) |
|
| |
| FVC% predicted at last spirometry, mean (std. dev.) | 92.96 (13.00) |
|
| |
| FEV1/FVC% predicted at first spirometry, mean (std. dev.) | 95.22 (7.23) |
|
| |
| FEV1/FVC% predicted at last spirometry, mean (std. dev.) | 94.27 (7.06) |